Concurrent Chemoradiation in Head and Neck Cancer

Primary Treatment Setting

The National Comprehensive Cancer Network recommends high-dose cisplatin at 100 mg/m² administered intravenously every 3 weeks as the preferred Category 1 chemotherapy regimen for concurrent chemoradiation therapy in head and neck cancer, delivering 2-3 cycles depending on the radiation fractionation scheme 1, 2, 3.
Single-agent cisplatin 100 mg/m² every 3 weeks achieved superior laryngeal preservation rates compared to induction chemotherapy or radiation alone in the RTOG 91-11 trial, with sustained benefit at 10-year follow-up 1.
The regimen is specifically recommended for locally advanced disease including T3-T4 tumors and N2-N3 nodal involvement 1.

The National Comprehensive Cancer Network recommends concurrent single-agent cisplatin at 100 mg/m² every 3 weeks for 3 doses for high-risk postoperative patients with extracapsular nodal extension and/or positive surgical margins 2, 3, 4, 5, 6.
This recommendation is based on two pivotal trials (EORTC 22931 and RTOG 9501) demonstrating improved locoregional control and survival with postoperative chemoradiation versus radiation alone 2, 3.

The National Comprehensive Cancer Network guidelines emphasize the importance of maintaining the 100 mg/m² dose unless specific toxicities mandate reduction per protocol 2, 3.
Patient selection is critical, and not all patients can tolerate concurrent therapy, requiring aggressive supportive care including antiemetics, hydration, nutritional support, and close monitoring 2, 3.
Inadequate supportive care can be a common pitfall, and chemoradiation requires an experienced multidisciplinary team with substantial supportive care infrastructure 2, 3, 4, 6.

The National Comprehensive Cancer Network recommends concurrent chemoradiation with cisplatin as the primary treatment for locally advanced head and neck cancers, delivering 70 Gy of radiation in 2.0 Gy fractions to primary tumor and gross adenopathy 7, 8
The National Comprehensive Cancer Network suggests chemoradiation in the postoperative setting for high-risk features such as extracapsular nodal extension and/or positive surgical margins, significantly improving locoregional control and survival 8, 9

The National Comprehensive Cancer Network prefers intensity-modulated radiation therapy (IMRT) to minimize dose to critical structures like salivary glands, temporal lobes, and auditory structures, particularly for head and neck cancers 7
The National Comprehensive Cancer Network notes that concurrent chemoradiation carries significant acute toxicities including mucositis, dermatitis, hematologic suppression, and nausea/vomiting requiring close monitoring and supportive care 8
The National Comprehensive Cancer Network recommends that the time from surgery to completion of radiotherapy should be kept as short as possible, ideally less than 6 weeks, for patients with high-risk features 9

The National Comprehensive Cancer Network emphasizes the importance of careful assessment of performance status and comorbidities in patient selection for concurrent therapy, as not all patients can tolerate the increased toxicity 8
The National Comprehensive Cancer Network recommends regular post-treatment surveillance, including baseline imaging within 6 months, regular physical examinations, and thyroid function monitoring if the neck was irradiated 8, 9

The European Organisation for Research and Treatment of Cancer (EORTC) 22931 trial demonstrated improved locoregional control with concurrent cisplatin compared with radiotherapy alone in high‑risk head and neck squamous cell carcinoma patients【10】.
The same EORTC 22931 trial showed improved disease‑free survival when cisplatin was added to postoperative radiotherapy【10】.
An overall survival advantage was observed in the EORTC trial but not in the RTOG 9501 trial, indicating that the survival benefit may depend on patient selection and trial design【10】.

Extracapsular nodal extension (ENE) and/or positive surgical margins (≤5 mm) are the only absolute pathological features that mandate the addition of cisplatin to postoperative radiotherapy, as identified by combined analyses of the landmark trials【10】.
The NCCN Guidelines incorporate these findings, recommending cisplatin‑based chemoradiotherapy only when ENE or close/positive margins are present【10】.

The NCCN endorses cisplatin 100 mg/m² administered every 3 weeks for three cycles as the traditional standard regimen for postoperative chemoradiotherapy【10】【11】.
Weekly cisplatin 40 mg/m² is now recognized as an evidence‑based alternative (supported by later trials such as JCOG1008), although this specific dosing recommendation is not directly cited in the provided references.

For patients with multiple positive lymph nodes without ENE, perineural invasion, vascular invasion, or pT4 primary tumors, the NCCN suggests considering postoperative chemoradiotherapy rather than mandating it【10】.
Combined analyses of the Bernier and Cooper trials revealed no survival advantage for the subgroup with multiple positive nodes but without ENE when cisplatin was added, supporting a more selective approach【10】.
Conversely, the EORTC 22931 trial demonstrated a survival benefit in a broader high‑risk cohort, creating clinical equipoise for the relative‑indication group【10】.